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ABSTRACT
Clostridium difﬁcile-associated diarrhoea (CDAD) presents mainly as a nosocomial infection, usually after
antimicrobial therapy. Many outbreaks have been attributed to C. difﬁcile, some due to a new hyper-
virulent strain that may cause more severe disease and a worse patient outcome. As a result of CDAD,
large numbers of C. difﬁcile spores may be excreted by affected patients. Spores then survive for months
in the environment; they cannot be destroyed by standard alcohol-based hand disinfection, and persist
despite usual environmental cleaning agents. All these factors increase the risk of C. difﬁcile
transmission. Once CDAD is diagnosed in a patient, immediate implementation of appropriate
infection control measures is mandatory in order to prevent further spread within the hospital. The
quality and quantity of antibiotic prescribing should be reviewed to minimise the selective pressure for
CDAD. This article provides a review of the literature that can be used for evidence-based guidelines to
limit the spread of C. difﬁcile. These include early diagnosis of CDAD, surveillance of CDAD cases,
education of staff, appropriate use of isolation precautions, hand hygiene, protective clothing,
environmental cleaning and cleaning of medical equipment, good antibiotic stewardship, and speciﬁc
measures during outbreaks. Existing local protocols and practices for the control of C. difﬁcile should be
carefully reviewed and modiﬁed if necessary.
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Levels of evidence [1]
Level 1a: Systematic review (with homogeneity) of
randomised controlled trials
Level 1b: Individual randomised controlled trial (with
narrow conﬁdence interval)
Level 1c: Studies with the outcome ‘All or none’
Level 2a: Systematic review (with homogeneity) of cohort
studies
Level 2b: Individual cohort study (including low-quality
randomised controlled trials; e.g., <80% fol-
low-up)
Level 2c: ‘Outcomes’ research; ecological studies
Level 3a: Systematic review (with homogeneity) of case–
control studies
Level 3b: Individual case–control study
Level 4: Case series (and poor quality cohort and case–
control studies)
Level 5: Expert opinion without explicit critical appraisal,
or based on physiology, bench research or
‘ﬁrst principles’
Categories for implementation in clinical practice
IA: Strongly recommended for implementation and
strongly supported by well-designed experimental,
clinical or epidemiological studies
IB: Strongly recommended for implementation and
strongly supported by some experimental, clinical or
epidemiological studies and a strong theoretical
rationale
IC: Required for implementation, as mandated by federal
and ⁄ or state regulation or standard (may vary
among different states ⁄ countries)
II: Suggested for implementation and supported by
suggestive clinical or epidemiological studies or a
theoretical rationale
Unresolved issue: Practices for which insufﬁcient
evidence exists or no consensus
regarding efﬁcacy exists
(no recommendation)
SCOPE OF THIS DOCUMENT
Several national guidelines concerning Clostridium
difﬁcile have been published, but they are often
adapted to the local situation in the individual
country or hospital and may not be appropriate in
other settings [2–5]. This literature review and the
recommendations contained in these guidelines
were stimulated by the increased incidence of
C. difﬁcile-associated diarrhoea (CDAD) in multi-
ple institutions and countries across Europe.
Control measures for C. difﬁcile differ in several
important ways from those used to reduce the risk
of other nosocomial pathogens. We recommend
that this document be used to produce and ⁄ or
review current local protocols for the control of
nosocomial CDAD. In particular, we emphasise
the need to determine local incidence on a real-
time basis, compare these data with a baseline
incidence (if available), and review practices
(including the review of local guidelines and their
implementation) as soon as an increased rate of
CDAD occurs. A change in the presentation of, or
complications associated with, CDAD, including
an increase in the severity of infection, should also
stimulate these actions, as this implies the intro-
duction and transmission of a new strain, poten-
tially with enhanced virulence.
BACKGROUND
Epidemiology
C. difﬁcile is the leading cause of intestinal infec-
tions related to antimicrobial therapy [6]. Factors
that may also predispose for CDAD include
increased age, duration of hospital stay, and
severity of underlying diseases [7–9]. The role of
proton pump inhibitors and other antacids in
CDAD development is still a matter of debate
[10,11]. Direct or indirect contact represents the
main route of C. difﬁcile transmission, as spores
may persist in the environment for months or
years and show resistance to various environ-
mental cleaners such as detergents and some
disinfectants [12–15]. Direct transmission via the
airborne route is unlikely to occur, but has been
suggested recently in a pilot study; the potential
for the dispersal of C. difﬁcile spores in air needs
further exploration [16].
A rapid change in the epidemiology of CDAD
has recently been reported and, notably, the
emergence and spread of a new hyper-virulent
strain belonging to PCR ribotype 027 [17]. This
phenomenon, together with background informa-
tion on pathogenesis, is described in more detail
elsewhere [18].
Clinical presentation, diagnosis and ﬁnancial
impact
Enterotoxin A and cytotoxin B represent the
major virulence factors of C. difﬁcile [14, 19]. Most
strains are able to produce both of these antigen-
ically distinct toxins. The severity of CDAD ranges
from mild diarrhoea to pseudo-membranous
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colitis or toxic megacolon and bowel perforation
in a few cases [20]. Crude mortality as a result of
CDAD varies according to the population affected
and may be as high as 25–30%, although the
attributable mortality is believed to be consider-
ably lower unless the hyper-virulent strain ribo-
type 027 is involved [21].
Currently, there are different diagnostic tests
for the recognition of CDAD. Detection of one or
both C. difﬁcile toxins may be performed by
cytotoxicity assay or by enzyme-linked immuno-
assays. C. difﬁcile strains not producing toxin A
are potentially being missed if an assay directed
only at this target is used. Alternative methods for
diagnosis of CDAD are culturing of toxin-pro-
ducing C. difﬁcile under anaerobic conditions or
(real-time) PCR-based approaches, directly from
stools [22].
First-choice therapeutic options for CDAD
include oral vancomycin or metronidazole [23].
A number of other therapeutic agents for treat-
ment of CDAD are being developed or available
but have not yet been approved for this indica-
tion. The average attributable cost for a case of
CDAD may add up to $8000 (= €6120) [24] and is




The following search strategy was applied to identify relevant
publications:
1 PubMed was searched using the search term ‘difﬁcile’ in
combination with either ‘nosocomial’, ‘outbreak’, ‘trans-
mission’, ‘control’, ‘environment’, and ‘prevention’.
2 The Cochrane Library was searched using the search term
‘difﬁcile’.
3 All outbreaks ﬁled in the Outbreak Database [25] were
explored using ‘C. difﬁcile’ as ‘species’ and the grouped-by
mode for ‘source’, ‘transmission’, and ‘measures’.
4 Finally, a manual search of the reference lists of all relevant
articles was performed in order to identify as yet unknown
publications that deal with infection control measures for
C. difﬁcile.
There were no restrictions with respect to language or type
of article.
Data evaluation
The quality of each individual study was determined by its
level of evidence according to the Oxford Centre for Evidence-
Based Medicine. As infection control measures for the
prevention of spread of enteric infections or multidrug-
resistant pathogens (especially pathogens that persist in the
environment, such as enterococci) may have some relevance
for C. difﬁcile, such recommendations (e.g., the HICPAC
guidelines for the management of multidrug-resistant organ-
isms and a systematic review on hand washing for the
prevention of diarrhoeal diseases) were also considered in
the preparation of this guideline [26–29].
The categories for implementation in clinical practice were
based on the categories in the HICPAC guideline documents,
ranging from ‘IA’ (strongly recommended for implementation
and strongly supported by well-designed experimental, clin-
ical, or epidemiological studies) to ‘unresolved issue’.
RESULTS
In total, 36 outbreaks caused by C. difﬁcile are
currently ﬁled in the Outbreak Database [24]. In
19 of these, the route of transmission could not be
determined or was not described by the authors
[30–48]. In the remaining 17, pathogen spread
occurred ‘by contact’ via carriage of spores on the
hands of staff [12,49–60], by patient-to-patient-
spread [13,52,54,59,61,62], or indirectly from the
contaminated environment [15,49,50,54,55,57,60].
There were few other infection control studies
that dealt with the transmission of C. difﬁcile
explicitly. The quality of the literature concerning
interventions to prevent CDAD is often limited
with respect to design, absence of details on
population, setting, nature and timing of inter-
ventions, failure to assess and adjust for con-
founders or bias, and use of inappropriate
statistical techniques [63,64]. Therefore, there is a
need for well-designed studies in each research
area of C. difﬁcile infection control [65].
CONCLUSIONS
Early diagnosis
The main purpose of screening cultures is to
identify carriers of pathogens at an early stage,
before cross-transmission can occur. The preva-
lence of C. difﬁcile carriage in asymptomatic and
otherwise healthy adult stool cultures is <5% [66].
In contrast, the rate of carriage among hospita-
lised patients varies signiﬁcantly and may be as
high as 25% [67–69]. More than half of the
C. difﬁcile strains isolated from symptom-free
individuals are toxinogenic [68,70].
Although screening cultures for C. difﬁcile have
been performed during some outbreaks
[30,37,46,60,61], there are no data showing that
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active screening of non-diarrhoeal patients to
identify C. difﬁcile carriers will contribute to a
reduction of the endemic baseline rate of CDAD.
However, asymptomatic carriers have recently
been reported to present a potential source of
C. difﬁcile transmission [71]. Besides reducing the
risk of pathogen spread, the second rationale for
screening cultures is to identify carriers who are
at risk of developing endogenous nosocomial
CDAD. However, in a prospective observational
study on long-stay patients, Johnson et al. [12]
showed that symptom-free excretors of C. difﬁcile
actually had a slightly decreased risk of subse-
quent CDAD (0 of 51 patients) as compared with
patients who had been initially culture-negative
(seven of 229 (3.1%) cases of CDAD). Shim et al.
[68] also observed that there were 22 cases of
CDAD among 618 previously non-colonised
patients (3.6%) as compared with two of 192
(1.0%) in symptom-free carriers (p 0.021). Addi-
tionally, treatment of asymptomatic carriers is
ineffective in eradicating C. difﬁcile [72]. Hence,
symptom-free C. difﬁcile colonisation may be pro-
tective against subsequent symptomatic disease,
but it is possible that asymptomatic carriers may
still contribute to transmission of the organism
[8,66,70,73–75].
Diarrhoeal patients are believed to represent
the major reservoir for C. difﬁcile transmission,
and are associated with the highest rates of
environmental contamination [76]. Diarrhoeal
stool samples should be processed as soon as
possible to diagnose CDAD. As recurrence of
CDAD after a symptom-free interval is common
(up to 20–50% of cases) [77–79], diagnostic testing
for C. difﬁcile should also be performed at a new
onset of diarrhoea. Environmental screening is
generally not recommended, but can be used to
document contamination or poor cleaning and
disinfection, especially in an outbreak situation.
A summary of the recommendations concern-
ing early diagnosis is given in Table 1.
Surveillance
Active surveillance of CDAD is recommended
[80]. Surveillance is useful to detect an increase in
CDAD incidence and severity at an early stage, or
to identify risk-factors for CDAD acquisition [81],
and should ideally include the identiﬁcation of
deaths in which CDAD is either the primary or
contributory cause. The signiﬁcance of surveil-
lance is not limited to outbreaks. In the endemic
setting, it may reveal high baseline rates or
signiﬁcant variations between locations that re-
quire interventions. Faecal testing for C. difﬁcile
toxins should be performed in the case of noso-
comial diarrhoea, and for all patients who have
been admitted for non-nosocomial diarrhoea.
Microbiology laboratories should test for C. difﬁ-
cile systematically in stool specimens from pa-
tients hospitalised for more than 3 days. This is
Table 1. Early diagnosis
Recommendations Category Evidence
1 Promptly perform tests for Clostridium difﬁcile toxins (± the
bacterium) in stool specimens in each case of nosocomial
diarrhoea and for individuals who are admitted with diar-
rhoea acquired outside the hospital. Stop repeated testing of
diarrhoeal stool samples as soon as C. difﬁcile has been
diagnosed. Only when a recurrence of CDAD is suspected,
repeat the C. difﬁcile testing and exclude other potential
causes of diarrhoea.
IB 3b [61], 4 [49,76,89]
2 Perform tests for C. difﬁcile or its toxins only on diarrhoeal
(unformed) stool specimens, unless ileus is present.
Testing of stool specimens from asymptomatic
patients is not recommended.
IB 2b [94,135], 3b [136], 4 [30,66]
3 Do not perform a ‘test of cure’ after treatment. IA 1a [23]
4 Faecal samples from all CDAD cases, and especially patients
(a) with severe CDAD (e.g., leading to admission to intensive
care unit, undergoing colectomy, or fatal cases), or (b) in an
outbreak situation, should be stored so that typing can be
performed, if necessary, retrospectively.
IB 1b [26], 3b [50], 4 [31,49,51,109]
CDAD, Clostridium difﬁcile-associated diarrhoea.
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sometimes referred to as the ‘3-day rule’ to
emphasise the greater value of testing for C. dif-
ﬁcile as opposed to conventional (community-
associated) enteric pathogens such as Salmonella,
Shigella and Campylobacter species [4]. If possible,
culture of C. difﬁcile toxin-positive samples, and
typing of isolates, should be available. In practice,
this is best achieved by storing aliquots of all
toxin-positive faecal samples, for examination
retrospectively, to aid C. difﬁcile cluster ⁄ outbreak
management, if necessary, by a reference labora-
tory.
A threshold CDAD incidence ⁄prevalence
should be deﬁned locally that would trigger
implementation of additional control interven-
tions. The alert level should be based on the
incidence, CDAD severity, institutional priorities,
whether the patient population has risk-factors
that may facilitate transmission or is at increased
risk of adverse outcomes following CDAD acqui-
sition, and whether there is suspected or proven
transmission.
A summary of the recommendations concern-
ing surveillance is given in Table 2.
Education and communication
Education of staff is one of the most effective
measures to limit C. difﬁcile spread [31,33,
37,50,52,62]. This should include information
about the basic pathogenic mechanisms, potential
reservoirs, route of transmission, contamination of
the environment, optimal decontamination of
hands ⁄ surfaces, and infection control measures
(in particular, contact precautions and glove use).
Training of staff should include not only medical
personnel (nurses or physicians), but also non-
medical personnel, especially those involved in
cleaning.
Education of visitors about contact precautions
is also necessary to prevent further spread of
spores [33]. Visitors should be encouraged to
basic infection control measures, with emphasis
on appropriate hand hygiene. Individuals suffer-
ing from acute diarrhoea themselves should not
visit patients in a hospital [82].
A summary of the recommendations concern-
ing education and communication is given in
Table 3.
Isolation precautions
Contact isolation is universally applied for pa-
tients with diseases that spread through contact.
The patient is preferably nursed in a single-
bedded room with dedicated equipment, and
personal protective clothing (gloves and gowns)
is used when contact with a patient occurs [83,84].
However, isolation for CDAD patients requires
additional and special measures for hand hygiene
and environmental cleaning, since C. difﬁcile
spores play an important role in the transmission
of infection.
Isolation of patients with infectious agents in
single rooms or cohorts is a basic hygiene mea-
sure of contact isolation to limit pathogen spread
[83,84]. Occasional reports note that a C. difﬁcile
outbreak ended following identiﬁcation of stored,
contaminated medical equipment as a point
source [85]. Usually, isolation of symptomatic
Table 2. Surveillance
Recommendations Category Evidence
1 Ensure routine surveillance of CDAD should be carried out
routinely in hospitals.
IB 2b [172], 3b [32], 4 [76,81], 5 [80]
2 Determine the unit-speciﬁc baseline incidence of CDAD by
reviewing results of faecal toxin tests or Clostridium difﬁcile
cultures.
IB 2c [173]
3 Deﬁne a threshold incidence or frequency of CDAD that would
trigger implementation of additional control interventions.
IB 2b [94,135]
4 Ensure appropriate and prompt diagnostic testing of patients
with an acute diarrhoeal illness not otherwise explained
(especially with diarrhoea associated with antimicrobial
therapy).
IB 3b [32], 4 [20]
5 Be alert for changes in the rate, complications (including
recurrences) or severity of CDAD that may indicate the
introduction of new strain(s).
Unresolved No data
CDAD, Clostridium difﬁcile-associated diarrhoea.
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patients with CDAD is the key measure to control
C. difﬁcile outbreaks [30,33,37,86,87]. Occasionally,
even closure of a complete ward ⁄department is
necessary [86,87]. Additionally, re-isolation of
patients presenting with diarrhoea at a subse-
quent readmission, who were previously known
to suffer from CDAD, may reduce the occurrence
of new nosocomial CDAD cases, reducing the
overall healthcare cost [88].
If daily clinical practice does not allow the
isolation of symptomatic patients in single rooms
on a regular ward, cohorting several patients on a
separate cohort ⁄ isolation ward may be consid-
ered. Staff on CDAD cohort wards may have
more experience in caring for such cases; cleaning
protocols for CDAD may be more easily facili-
tated in separate areas; materials used on a cohort
ward are usually not used elsewhere; and there
are fewer people entering a cohort ward unnec-
essarily. Another possible positive effect of
cohorting is to localise environmental contamina-
tion to a small part of the hospital. This is
different from having isolation rooms used for
CDAD dispersed throughout a hospital in numer-
ous locations. Each failure of hygiene in these
locations represents a high risk of extended local
contamination and secondary cases. The overall
effect may be to reduce signiﬁcantly the burden of
environmental contamination to a single focus
(cohort ward), where it is recognised and con-
tainable [89].
Apart from isolation procedures, it is essential
that patients suffering from any form of diarrhoea
have a dedicated toilet or commode; i.e. they
should not be allowed to use general toilet
facilities.
One critical issue is for how long isolation and
other control measures need to be continued. Few
data are available on the excretion of vegetative
cells ⁄ spores during an episode of CDAD. The
consensus is that nosocomial outbreaks can be
terminated if precautions are kept in place until
bowel functioning has returned to normal for at
least 48 h [33]. The environment of symptomatic
patients with CDAD is more frequently contam-
inated than that of asymptomatic carriers [67].
However, even after adequate therapy for CDAD
and return to normal bowel movements, patients
may still have detectable C. difﬁcile toxins in
faeces and continue to excrete C. difﬁcile. It is
possible for up to 30% of stool samples to remain
toxin-positive in patients treated with vancomy-
cin or metronidazole [90], and a correlation
between stool cytotoxin levels and severity of
gastrointestinal symptoms may not be present in
all cases [19]. There is, however, no clinical value
in retesting CDAD cases once symptoms resolve;
i.e., knowing the carriage status of patients has no
known clinical beneﬁt, as a role for asymptomatic
carriers in the spread of C. difﬁcile has not been
deﬁned. Basic hygiene measures must therefore
be an integral part of normal practice. Further-
more, for most other pathogens, alcohol-based
hand hygiene is recommended, unless major
contamination of hands has occurred, and then
guidance must be provided locally with regard to
recommencement (see below) [91].
A summary of the recommendations concern-
ing isolation precautions is given in Table 4.
Hand hygiene
Hand hygiene is the primary action to reduce
healthcare-associated infections [92]. Thus, hand
hygiene guidelines have been revisited and
should improve standards and practices [93].
Standard hand hygiene practices today use alco-
hol-based products, unless hands are in contact
with body ﬂuids or are visibly contaminated.
When hands are clearly contaminated, decontam-
ination by soap-based washing has to be
performed (possibly prior to hand disinfection)
[91–93]. It is clear that the hands of healthcare
workers (HCWs) are likely to become contami-
nated when caring for patients with CDAD
[35,67,75,94]. Unfortunately, bacterial spores are
Table 3. Education and communication
Recommendation Category Evidence
1 Everyone who enters a patient’s room ⁄ environment, including
healthcare workers and visitors, should be educated about
the clinical features, transmission and epidemiology of
CDAD.
IA 1a [156,157], 2b [172],
4 [86,174], 5 [128]
CDAD, Clostridium difﬁcile-associated diarrhoea.
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not killed by alcohols [95], and, indeed, alcohol is
used in the laboratory setting to select for C. dif-
ﬁcile spores. Importantly, none of the other agents
(chlorhexidine, hexachlorophene, iodophors,
chloroxylenol, or triclosan) used in antiseptic
hand-wash or hand-rub preparations is reliably
effective against C. difﬁcile spores [93]. In an
experimental study using hands of volunteers
contaminated by C. difﬁcile, Barbut et al. [96]
showed that 4% polyvidone soap was signiﬁ-
cantly more effective in reducing the C. difﬁcile
count than chlorhexidine or non-medicated soap,
and these products were also more effective than
alcohol-based products. In a recent observational
study, the introduction of alcohol-based hand rub
was not associated with an increase in the
incidence of nosocomial CDAD (3-year incidence
per 10 000 patient-days before, 3.24; 3-year inci-
dence after, 3.38; p 0.78) [97]. Boyce et al. showed
that a ten-fold increase in the use of alcohol-based
hand rub (p <0.001) within 4 years did not alter
the incidence of CDAD [98]. Bacterial spores can
be removed from hands by the physical action of
washing and rinsing [91,94], using either non-
antimicrobial liquid soap or antiseptic substances
such as chlorhexidine. In a crossover study, no
differences in residual counts of C. difﬁcile on bare
hands were observed after comparing liquid soap
and chlorhexidine gluconate [99], while others
found signiﬁcantly improved removal of spores
on HCWs who used soap containing chlorhexi-
dine gluconate as compared to non-disinfectant
soap (p <0.01) [67]. Leischner et al. recently found
that alcohol gels were signiﬁcantly less effective at
removing C. difﬁcile spores from the hands of
volunteers than hand washing with chlorhexidine
(p <0.009). However, in their study, there was a
higher than expected reduction of spore counts
following use of alcohol gels [100]. Although
gloving will dramatically reduce the degree of
contamination of hands by C. difﬁcile spores, there
is still a need for optimal hand hygiene after
removal of gloves [93].
The role of the patient remains uncertain in the
transmission of C. difﬁcile, although direct person-
to-person transmission has been proposed
[61,94,101]. Endogenous infections can also occur,
in principle, even though there are some data
suggesting that primary C. difﬁcile carriage, or
carriage in the absence of ever having CDAD, is
relatively protective against CDAD [73]. Thus,
hand washing by patients should be strongly
encouraged [86], especially after a toilet visit and
before eating.
A summary of the recommendations concern-
ing hand hygiene is given in Table 5.
Protective clothing
The use of gloves to protect the hands of HCWs
from contamination is generally recommended
by the HICPAC as a part of contact precautions
[102]. Since none of the agents used in antiseptic
hand-wash or antiseptic hand-rub preparations
is reliably sporocidal against C. difﬁcile spores,
HCWs should be encouraged to wear gloves
when caring for patients with CDAD. In a
prospective controlled trial of vinyl glove use
Table 4. Isolation precautions
Recommendations Category Evidence
1 Patients with CDAD represent a source for pathogen spread to
others and should be isolated in single rooms whenever
possible.
IB 1b [26,102], 2b [84,172]
2 A designated toilet or commode (transportable toilet) for
CDAD patients should be provided.
IB 1b [26,102]
3 If isolation in single rooms is not possible, isolation in cohorts
should be undertaken. If there is a lack of capacity, then
consideration should be given to using a designated ward or
unit for cohort isolation.
IB 1b [26,102], 4 [86,89]
4 Cohorted patients should be managed by designated staff to
minimise the risk of cross-infection to other patients.
IB 1b [26], 4 [86]
5 Isolation precautions may be discontinued 48 h after
symptomatic CDAD has resolved and bowel movements have
returned to normal.
II 4 [33,34,175]
CDAD, Clostridium difﬁcile-associated diarrhoea.
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to prevent C. difﬁcile spread, the incidence of
CDAD decreased signiﬁcantly from 7.7 to 1.5 per
1000 patient discharges within a 6-month inter-
vention period [103]. In another observational
study, the hands of all four members of staff
using gloves remained free of C. difﬁcile spores.
This contrasts with hand contamination in seven
of 15 staff who did not use gloves and did not
observe further hand hygiene practices [67].
Contaminated gloves need to be removed prior
to touching non-contaminated surfaces [52].
Contamination of hands may occur during
removal of contaminated gloves [104]. Therefore,
hand washing and drying remain important
regardless of previous glove use.
Gowns and aprons represent an additional step
in infection control standard precautions to pre-
vent contamination of the regular working clothes
by infectious agents, and should therefore be used
when caring for known CDAD cases
[30,33,37,86,102]. Few data exist on the use of
gowns speciﬁcally to prevent inter-patient spread
of C. difﬁcile. Perry et al. [105] showed C. difﬁcile
contamination of nurses’ uniforms during work
and therefore recommended the wearing of
appropriate plastic aprons; some nurses’ uni-
forms were already C. difﬁcile-positive before
duty. Uniforms had been laundered by staff at
home, but no information on whether these were
ironed or how they were stored was provided. A
hospital laundry service may be preferable to
home laundry for the elimination of spores in the
washing process. However, it should be emphas-
ised that recovery of C. difﬁcile from uniforms
could simply represent either direct or indirect
contamination (e.g. from the environment) and
does not necessarily implicate such fomites in
transmission.
A summary of the recommendations con-
cerning protective clothing is given in Table 6.
Table 5. Hand hygiene
Recommendations Category Evidence
1 Besides the use of gloves, meticulous hand
washing with soap and water is recom-
mended for all staff after contact with body
substances, or following any other potential
contamination of hands when caring for
known CDAD patients. The physical action of
rubbing and rinsing is the only way to remove
spores from hands. Washing of hands using
water and soap is also recommended after the
removal of gloves or aprons used during
contact with individual patients.
IB 2a [91], 2a [27], 2b [67,94,97],
2c [99], 4 [52]
2 There is no recommendation for the use of a
soap that contains antiseptic substances.
Unresolved 2c [99]
3 Alcohol-based hand rub should not be the only
hand hygiene measure when caring for sus-
pected or proven Clostridium difﬁcile positive
patients.
IB 2b [97,98], 2c [99,176]
CDAD, Clostridium difﬁcile-associated diarrhoea.
Table 6. Protective clothing
Recommendations Category Evidence
1 Healthcare workers should wear gloves for contact with a
CDAD patient; this includes contact with body substances,
and ⁄ or potentially contaminated environment (including the
immediate vicinity of the patient).
IB 1b [26,102], 2b [67,103]
2 Gowns or aprons should always be used for managing patients
who have diarrhoea.
IB 1a [177], 1b [26,102], 4 [105]
CDAD, Clostridium difﬁcile-associated diarrhoea.
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Environmental cleaning
It is well-documented that environmental con-
tamination occurs as a result of CDAD, especially
if patients have large amounts of liquid stool or
stool incontinence [35,52,53,59,74,75,94,106].
Remarkably heavy contamination takes place on
ﬂoors, commodes, toilets, bed pans, and bed
frames [62,67,96,106–108]. The actual degree of
spore recovery from environmental swabs may
directly correlate with the incidence of CDAD
[75,94,107–109], although a recent molecular epi-
demiological study was unable to determine
whether environmental contamination is the con-
sequence of CDAD or the source of infection,
primarily because of the often clonal nature of
nosocomial CDAD [109]. Once released in the
environment, C. difﬁcile spores may persist for
long periods (months or years), due to their
resistance to drying, heat, and disinfection sub-
stances [110,111].
There is good evidence that environmental
contamination plays a role in C. difﬁcile transmis-
sion [112,113]. Cleaning with detergents only may
be insufﬁcient for environments contaminated
with C. difﬁcile [107], and there is a need for
effective and user-friendly sporocidal products
[114]. Various disinfection substances are avail-
able to inactivate C. difﬁcile spores; however, sub-
inhibitory concentrations of some disinfectants or
non-chlorine-based products may enhance spor-
ulation [115]. The sporulation capacity of out-
break strains such as ribotypes 027 or 001 may
also exceed that of other C. difﬁcile strains. In the
current CDC ⁄HICPAC guidelines, no speciﬁc
disinfection agent for standard environmental
control of C. difﬁcile is recommended (i.e., in the
absence of known CDAD cases) [116].
Hypochlorite-based disinfectants are recom-
mended by the HICPAC for regular use, espe-
cially on frequently touched surfaces in patient
care areas where surveillance indicates ongoing
C. difﬁcile transmission [116], and are frequently
used in many hospitals [53,86,106]. It is of
potential importance that chlorine-based products
are signiﬁcantly less likely to enhance sporulation
of C. difﬁcile strains in vitro [115]. In comparison
with cleaning with a detergent only, hypochlorite
use at a concentration of 1000 parts per million
(p.p.m.) was associated with a signiﬁcant reduc-
tion in the incidence of CDAD on one of two
study wards [108,117,118]. Phosphate-buffered
hypochlorite (1600 p.p.m. available chlorine)
may be more effective against C. difﬁcile spores
than unbuffered hypochlorite solution (500 p.p.m.
chlorine) [53]. A possible disadvantage that needs
to be considered in the choice of disinfectants is
the corrosive nature of hypochlorite on metal
surfaces [119], especially if very high concentra-
tions are used (e.g. 5000 p.p.m. available chlo-
rine). Furthermore, products containing
hypochlorite alone are not suitable for removing
organic matter. Products containing a combina-
tion of hypochlorite and a detergent may over-
come this problem.
Quarternary ammonium (QA) solutions have
also been used for environmental C. difﬁcile
decontamination [94]. However, while no differ-
ences in the CDAD incidence were observed in
patient care areas with low CDAD incidences, the
change from QA solutions to unbuffered 1:10
hypochlorite (5000 p.p.m. available chlorine) for
disinfection in the rooms of CDAD-positive
patients in a bone marrow transplant unit led to
a signiﬁcant reduction in the incidence of CDAD
(8.6–3.3 per 1000 patient-days); the incidence of
CDAD increased to 8.1 per 1000 patient-days after
reverting back to QA cleaning [118].
Hydrogen peroxide vapour recently proved to
be effective in environmental C. difﬁcile eradica-
tion. However, this method is expensive and
involves having to vacate and seal clinical areas. It
does not address the issue of recontamination,
which may occur on a daily basis.
Glutaraldehyde is known to be effective in
inactivation of C. difﬁcile spores [120] and has
been used for this purpose in nosocomial C. dif-
ﬁcile outbreaks [85]. However, due to risks to
human health, and for environmental safety
reasons, it should not be used for environmental
decontamination.
Peracetic acid 0.2% is more active in vitro than
chlorine-releasing agents such as sodium dichlo-
roisocyanurate at 1000 p.p.m. available chlorine
[121]. This high-level disinfection substance may
also be a substitute for glutaraldehyde [122],
although long contact times of 15–20 min are
required [123]. Peracetic acid has not been used
for environmental decontamination.
For eradicating C. difﬁcile spores from the envi-
ronment, the maximum permissible concentration
of chemicals (e.g. chlorine) may differ depending
upon national health and safety regulations. Each
organisation responsible for cleaning hospitals
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should have speciﬁc protocols for the treatment of
rooms of patients with CDAD. All objects fre-
quently touched by patients and staff, such as
tables, chairs, or telephones, should be disinfected
at least once a day. In clinical practice, it is
essential to educate cleaning personnel on a
regular basis, especially emphasising the differ-
ence in cleaning and disinfection of areas used by
patients with CDAD and those used by patients
colonised ⁄ infected by methicillin-resistant Staph-
ylococcus aureus or other multidrug-resistant
pathogens.
A summary of the recommendations concern-
ing environmental cleaning is given in Table 7.
Use of medical equipment
Ideally, for medical equipment that cannot be
easily decontaminated, disposable items should
be used to control CDAD outbreaks [85]. Notably,
rectal thermometers can play a signiﬁcant role in
transmission of C. difﬁcile. Although electronic
thermometers do not necessarily become contam-
inated with C. difﬁcile [52], there are numerous
investigations in which positive C. difﬁcile cul-
tures were obtained from these devices. For
example, Samore et al. showed that three of 38
thermometers became contaminated by C. difﬁcile
during use [94]. Shared rectal thermometers
should therefore be replaced by individual ther-
mometers [35], or alternatively, a change to
tympanic thermometers should be considered,
as these have been associated with a 40% risk
reduction [54]. An even greater risk reduction
(56%; p 0.026) was accomplished by using dis-
posable vs. shared electronic thermometers in a
randomised crossover study [124].
There have been no reports of endoscopes
transmitting C. difﬁcile in the hospital setting.
However, Hughes et al. [125] found that ten of 15
endoscopes were contaminated with C. difﬁcile
immediately after use in patients with CDAD.
Since single use is not an option for such expensive
equipment, endoscopes need to be re-processed
adequately before further use. Disinfection of
endoscopes with alkaline glutaraldehyde solution
2% or with peracetic acid led to inactivation of
C. difﬁcile spores after thorough cleaning and an
exposure time of 5–10 min [120,125,126]. Thus,
endoscope cleaning followed by exposure to
sporocidal disinfectants or thermal re-processing,
as is standard in most hospitals, should be
adequate for killing of C. difﬁcile spores.
Additional devices found to be C. difﬁcile-
positive include blood pressure cuffs [52,59] and
oximeters [94]. Although it tested negative in one
investigation [85], equipment for enemas may
also be critical in this context. In general, instru-
ments and equipment, including stethoscopes
and blood pressure cuffs, should be patient-
speciﬁc and cleaned carefully after use.
A summary of the recommendations concern-
ing the use of medical equipment is given in
Table 8.
Table 7. Environmental cleaning
Recommendations Category Evidence
1 Regular environmental disinfection of rooms of CDAD patients
should be done using sporocidal agents, ideally chlorine-
containing agents (at least 1000 p.p.m. available chlorine). The
choice of cleaning regimen will depend on local policy.
IB 2b [108], 2c [115,117], 4 [53]
2 Hospital wards should be cleaned regularly (at least once a
day), concentrating on frequently touched surfaces.
IB 1b [26], 2a [116], 4 [107]
3 Cleaning staff should be notiﬁed immediately when environ-
mental faecal soiling has occurred. Cleaning needs to be done
as soon as possible.
IB 1b [26], 2a [116]
4 Toilets and items such as commodes and bed pans, which are
likely to be faecally contaminated, are important sources of
Clostridium difﬁcile spores and must therefore be cleaned
scrupulously. Cleaned commodes and bed pans should be
stored under dry conditions.
IB 1b [26], 2a [116]
5 After discharge of a CDAD patient, rooms must be cleaned and
disinfected thoroughly.
IB 2b [178], 2c [121], 5 [114]
CDAD, Clostridium difﬁcile-associated diarrhoea.
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Good antibiotic stewardship
Antibiotic therapy or prophylaxis [127] alters the
colonic microbiota and potentially allows C. difﬁ-
cile to proliferate, produce toxins, and cause
diarrhoea [6]. Antibiotics constitute the most
important predisposing factor for CDAD
[7,9,128]. However, a systematic review of the
studies that have examined the risk of CDAD
associated with different antibiotics revealed that
most are ﬂawed because of failure to control for
potential confounding factors [129]. Exposure to
C. difﬁcile, therapy with a combination of, or
sequential, antibiotics and duration of antibiotics
are frequently not addressed as causes of bias
[129,130]. Furthermore, host humoral immunity
to C. difﬁcile toxin(s) and the antibiotic suscepti-
bility of the C. difﬁcile strain are likely to inﬂuence
the risk of CDAD development [131,132]. It is not
surprising, therefore, that there are conﬂicting
studies regarding the risk of CDAD in relation to
speciﬁc antibiotics or classes. Good antibiotic
stewardship should be promoted as standard,
and CDAD cases can be used to reinforce such
principles [133].
A policy for prudent use of antibiotics should
be an evidence-based approach to reduce the
incidence of CDAD, but the application will vary
among countries and institutions. A recent study
from Canada reported no change in CDAD
incidence after strengthening of infection control
procedures, but implementation of an antimicro-
bial stewardship programme was followed by a
marked reduction in incidence. This suggests that
non-restrictive measures to optimise antibiotic
usage can yield exceptional results when physi-
cians are motivated and that such measures
should be a mandatory component of CDAD
control [134]. However, in practice, in virtually all
situations where CDAD rates increase, changes in
antibiotic usage are implemented in addition to
enhancements of infection control measures.
Thus, the true effect of restrictive or non-restric-
tive antibiotic control measures alone on CDAD
rates is difﬁcult to assess.
Almost any antibiotic may induce CDAD, but
broad-spectrum cephalosporins (in particular,
second- and third-generation cephalosporins),
broad-spectrum penicillins and clindamyin are
most frequently implicated [31,129,135–145].
Since 2000, ﬂuoroquinolones have also been iden-
tiﬁed as a possible risk-factor for CDAD, includ-
ing CDAD caused by the new hyper-virulent PCR
ribotype 027 [34,36,50,55,146–148]. The PCR rib-
otype 027 strain of C. difﬁcile is resistant to
ﬂuoroquinolones, and increased use of these
antibiotics may have contributed to some out-
breaks. Fluoroquinolones, especially ciproﬂoxa-
cin, were associated with the highest relative risk
for CDAD due to PCR ribotype 027 C. difﬁcile in
Canada and The Netherlands [146,149]. However,
in the above-mentioned study that reported that
the implementation of an antimicrobial steward-
ship programme led to a marked reduction in
CDAD incidence, respiratory ﬂuoroquinolone
usage had increased by 79% [134].
Ureidopenicillins (with or without b-lactamase
inhibitors) appear to have a low propensity to
induce CDAD [143,150,151]. The reasons why
anti-pseudomonal penicillins appear rarely to
promote C. difﬁcile infection as compared with
cephalosporins may include relative activity
against C. difﬁcile itself and the absence of a
propensity to select and ⁄ or induce spore germi-
nation. In a gut model, despite widespread
disruption of bacterial populations during piper-
Table 8. Use of medical equipment
Recommendations Category Evidence
1 Medical devices such as blood pressure cuffs should be
dedicated to a single patient.
IB 1b [26,177], 4 [52]
2 All equipment should carefully be cleaned and disinfected
using a sporocidal agent immediately after use on a CDAD
case.
IB 1b [102], 2c [125], 4 [52]
3 Thermometers should not be shared and use of electronic
thermometers with disposable sheaths should be avoided.
IA 1b [124], 2b [35,54,94]
4 The use of disposable materials should be considered whenever
possible.
IB 1b [26], 4 [85]
CDAD, Clostridium difﬁcile-associated diarrhoea.
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acillin–tazobactam administration, C. difﬁcile pop-
ulations remained principally as spores, and no
sustained proliferation or high-level cytotoxin
production was seen [152].
Many hospital inpatients receive combinations
of antibiotics or multiple antibiotic courses. Given
that antibiotic use is unnecessary or inappropriate
in as many as 50% of cases, a Cochrane analysis
indicated that interventions to improve antibiotic
prescribing can reduce hospital-acquired infec-
tions, most notably CDAD [31,63,153]. The exact
duration of risk of developing CDAD after anti-
biotic exposure still needs to be determined, but
there is some evidence that the duration of
therapy with certain antibiotics may also inﬂu-
ence this risk [146]. Aggressive restriction of
high-risk antibiotics, reducing polypharmacy,
prevention of long-term therapy and avoiding
inappropriate prescribing are the ﬁrst steps in
reducing a high incidence of CDAD. Some mea-
sures to achieve this goal comprise automatic
stop-dates, electronic prescribing [154], banning
of certain antibiotics [34], prescriber education,
and production of guidelines or policies [4,133].
There is also a need for continuous training of
medical staff about appropriate antimicrobial use
and for feedback of success [150,155], since
systematic reviews have shown the positive effect
of audit and feedback in helping HCWs to
implement evidence-based practice [156–159]. In
a controlled, interrupted time-series on a geriatric
ward, Fowler et al. showed that feedback on
improved antibiotic prescribing can be successful
in reducing the use of broad-spectrum antibiotics
(amoxycillin–clavulanic acid and cephalosporins)
in favour of more pathogen-focused treatment
(benzylpenicillin and trimethoprim). Conse-
quently, the altered antimicrobial treatment reg-
imen was associated with a signiﬁcant decrease in
CDAD (p 0.009) [137]. Deﬁning so-called ‘alert
antimicrobials’, drugs that need patient-speciﬁc
feedback by an authorised person (e.g., the
hospital pharmacist), may also be useful to
further improve antibiotic use in the hos-
pital [160]. In addition, surveillance of hospital
antibiotic use (at least of the ‘high-risk’ agents
mentioned above) by pharmacists, in close coop-
eration with medical microbiologists, is recom-
mended [137,161].
Exposure to antibiotics is believed to lead to
disturbance of the normal gastrointestinal micro-
biota. This may predispose to diarrhoea after
acquisition (or selection) and proliferation of
C. difﬁcile. Probiotics (bacteria and yeasts) are
thought to restore the balance of the gut microbi-
ota when administered orally to patients. At
present, few data exist on the treatment or pre-
vention of CDAD with probiotics. There are some
randomised controlled trials that show a signiﬁ-
cant reduction in the risk of antibiotic-associated
diarrhoea by the use of Saccharomyces boulardii
[162,163], but newer studies using S. boulardii or
Lactobacillus GG failed to conﬁrm these ﬁndings
[164,165]. Three published systematic reviews did
not show sufﬁcient evidence to support the use of
probiotics for CDAD prevention or treatment
[166–168]. It was claimed that the results of a
recent trial with a Lactobacillus preparation
showed a beneﬁcial effect of probiotics in antibi-
otic-associated diarrhoea [169]. However, the
design of this study has been criticised, because
the highly selective inclusion and exclusion crite-
ria meant that <7% of the potential target popu-
lation was examined, and the use of a milk-based
placebo may have introduced bias [170].
A summary of the recommendations concern-
ing good antibiotic stewardship is given in
Table 9.
Speciﬁc measures in outbreaks
The key to reducing risk of infection is the
prevention of transmission of C. difﬁcile. When
an increased number of cases of C. difﬁcile is
identiﬁed, the infection control strategy should be
informed by risk assessment that takes into
Table 9. Good antibiotic stewardship
Recommendation Category Evidence
1 Stop any (non-Clostridium difﬁcile) antimicrobial treatment in a
patient with CDAD as soon as possible.
IA 1a [23]
Further recommendations concerning the use of antibiotics apply to an outbreak situation or settings with high endemicity.
Please refer to Table 10 (4). CDAD, Clostridium difﬁcile-associated diarrhoea
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account the background epidemiological pattern
and the risk status of the patients involved.
Outbreak situations require immediate action.
Usually, this involves a combination of different
infection control measures [171]. Hence, the effec-
tiveness of each individual measure is difﬁcult to
determine. First of all, adherence to recommen-
dations that apply in the endemic setting needs to
be strengthened. These measures include strict
separation of symptomatic patients, education of
staff, increased awareness of CDAD, and restric-
tion of the use of high-risk antibiotics [37]. Zafar
et al. [172] reported a 60% reduction in the rate of
CDAD following implementation of isolation,
surveillance, education, environmental disinfec-
tion, optimal hand washing, and centralised
re-processing of devices. Struelens et al. [76]
observed a 73% decrease in CDAD incidence as
a result of early isolation precautions, active
initial surveillance, environmental surface disin-
fection, and early therapy for CDAD.
Speciﬁc measures may be helpful in a nosoco-
mial CDAD outbreak. Early and rapid diagnosis
is important. Also, the threshold should be low
for the rapid evaluation of patients with mild
diarrhoea on wards with active cases of CDAD.
Cohort nursing of conﬁrmed CDAD patients, and
isolation of suspected CDAD cases before labora-
Table 10. Speciﬁc measures during outbreaks
Recommendations Category Evidence
1 Infection control staff should always be
informed when there is an increased number
or severity of CDAD cases.
IB 1b [26]
2 All hygiene measures should be reinforced in
case of a CDAD outbreak.
IB 1b [26], 4 [89]
3 Review the standard of environmental cleaning
to ensure high quality and frequency of
decontamination. If possible, implement a
designated and well-educated cleaning team
especially for the rooms of CDAD patients.
II 4 [86]
4 Perform good antibiotic stewardship. Antimi-
crobial prescribing (frequency, duration, and
types of agents) should be reviewed as soon as
possible, with emphasis on avoiding the use of
high-risk agents (e.g. cephalosporins, ﬂuor-
oquinolones and clindamycin) in at-risk pa-
tients. Use these agents only when medically
needed.
IB 1a [133], 2b [7,31,135,137,146],
3b [36,50,55,136,138–140,147,148],
4 [32,34,37,38]
5 Faecal samples from all CDAD cases should be
stored, so that they can be cultured, either
locally or in a reference laboratory, and typing
can performed, if necessary, retrospectively.
IB 1b [26], 3b [50], 4 [31,49,51,109]
6 In order to elucidate the epidemiology of
Clostridium difﬁcile, isolates from infected
patients should ideally be compared by
molecular methods.
II 2b [94]
7 Implement interim policies for patient admis-
sions, placement, and stafﬁng as needed to
prevent C. difﬁcile transmission.
IB 1b [26]
8 For details on isolation procedures and
dedicated nursing staff, please refer to Table 4.
9 When transmission continues despite the
assignment of dedicated staff, close the unit
or facility to new admissions.
IB 1b [26]
10 When transmission continues despite all of the
above measures (e.g. re-opened unit), vacate
the unit for intensive environmental cleaning
to eliminate all potential environmental res-
ervoirs of C. difﬁcile.
II 2a [26]
CDAD, Clostridium difﬁcile-associated diarrhoea.
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tory test results are available, have been shown to
be effective during a CDAD outbreak [46]. In a
recently published report of an epidemic of CDAD
on a geriatric ward, Cheriﬁ et al. [89] reported that
cohorting of infected patients on one ward with a
single medical team was a key way of limiting the
spread of infection. However, the capacity to
establish a dedicated unit and nursing team for
CDAD patients will need to be considered along-
side competing pressures. Similarly, the measures
used in outbreaks may depend on the wards
involved and on the clinical severity of cases.
However, a written local protocol should exist
so that early adoption and ⁄ or review of control
measures occurs when CDAD cases are identiﬁed.
An additional key to CDAD prevention is to
reduce the number of susceptible patients. This
can result from good antimicrobial stewardship,
which will minimise the antimicrobial exposure
of patients in the hospital, thus reducing the
number of patients susceptible to developing
CDAD even if C. difﬁcile transmission occurs
[133].
A summary of the recommendations concern-
ing speciﬁc measures during outbreaks is given in
Table 10.
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